RPR 106972（一种新型口服链阳菌素）、头孢妥仑（一种新型口服头孢菌素）、两种新型恶唑烷酮（U-100592和U-100766）以及其他口服和胃肠外用药对203株青霉素敏感和耐药肺炎球菌的活性。
Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci.
作者信息
Spangler S K, Jacobs M R, Appelbaum P C
机构信息
Department of Pathology (Clinical Microbiology), Hershey Medical Center, Pennsylvania 17033, USA.
出版信息
Antimicrob Agents Chemother. 1996 Feb;40(2):481-4. doi: 10.1128/AAC.40.2.481.
Abstract
Agar dilution was used to determine the MICs of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents for 203 penicillin-susceptible and -resistant pneumococci. All pneumococci were inhibited by RPR 106972 at < or = 0.5 microgram/ml. Cefditoren was very active against all pneumococcal groups, with MICs of < or = 2.0 micrograms/ml. Amoxicillin with or without clavulanate was the next most active oral beta-lactam, followed by cefdinir, cefuroxime, cefpodoxime, and cefprozil. U-100592 and U-100766 were very active against all classes of pneumococci, with all MICs < or = 1.0 microgram/ml.
摘要
采用琼脂稀释法测定了RPR 106972（一种新型口服链阳菌素）、头孢妥仑（一种新型口服头孢菌素）、两种新型恶唑烷酮（U - 100592和U - 100766）以及其他口服和胃肠外用药对203株青霉素敏感和耐药肺炎球菌的最低抑菌浓度（MIC）。所有肺炎球菌对RPR 106972的MIC均≤0.5微克/毫升。头孢妥仑对所有肺炎球菌群均具有很高活性，MIC≤2.0微克/毫升。含或不含克拉维酸的阿莫西林是活性次之的口服β-内酰胺类药物，其次是头孢地尼、头孢呋辛、头孢泊肟和头孢丙烯。U - 100592和U - 100766对所有类型的肺炎球菌均具有很高活性，所有MIC均≤1.0微克/毫升。
相似文献
1
Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci.
Antimicrob Agents Chemother. 1996 Feb;40(2):481-4. doi: 10.1128/AAC.40.2.481.
2
In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae.
Antimicrob Agents Chemother. 1996 Apr;40(4):1039-40. doi: 10.1128/AAC.40.4.1039.
3
Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
Clin Ther. 2003 Jan;25(1):169-77. doi: 10.1016/s0149-2918(03)90021-x.
4
MIC and time-kill study of antipneumococcal activities of RPR 106972 (a new oral streptogramin), RP 59500 (quinupristin-dalfopristin), pyostacine (RP 7293), penicillin G, cefotaxime, erythromycin, and clarithromycin against 10 penicillin-susceptible and -resistant pneumococci.
Antimicrob Agents Chemother. 1996 Sep;40(9):2071-4. doi: 10.1128/AAC.40.9.2071.
5
Time-kill studies on susceptibility of nine penicillin-susceptible and -resistant pneumococci to cefditoren compared with nine other beta-lactams.
J Antimicrob Chemother. 1997 Feb;39(2):141-8. doi: 10.1093/jac/39.2.141.
6
In vitro susceptibility of 90 penicillin-susceptible and -resistant pneumococci to penicillin G, amoxicillin, amoxicillin/clavulanate, cefaclor, cefuroxime, cefpodoxime, cefixime and imipenem.
Folia Microbiol (Praha). 1998;43(1):68-70. doi: 10.1007/BF02815546.
7
In vitro activity of cefditoren and other antimicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain.
Diagn Microbiol Infect Dis. 2008 Oct;62(2):210-5. doi: 10.1016/j.diagmicrobio.2008.06.007. Epub 2008 Aug 20.
8
In vitro activity of oral cephalosporins against pediatric isolates of Streptococcus pneumoniae non-susceptible to penicillin, amoxicillin or erythromycin.
J Chemother. 2008 Apr;20(2):175-9. doi: 10.1179/joc.2008.20.2.175.
9
Influence of the beta-lactam resistance phenotype on the cefuroxime versus cefditoren susceptibility of Streptococcus pneumoniae and Haemophilus influenzae recovered from children with acute otitis media.
J Antimicrob Chemother. 2007 Aug;60(2):323-7. doi: 10.1093/jac/dkm209. Epub 2007 Jun 11.
10
In vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporin cefditoren.
Diagn Microbiol Infect Dis. 2002 Jan;42(1):59-64. doi: 10.1016/s0732-8893(01)00304-2.
引用本文的文献
1
Contezolid Harbored Equivalent Efficacy to Linezolid in Tuberculosis Treatment in a Prospective and Randomized Early Bactericidal Activity Study.
Infect Drug Resist. 2025 Jan 13;18:261-268. doi: 10.2147/IDR.S499816. eCollection 2025.
2
Identification of Novel Antibacterials Using Machine Learning Techniques.
Front Pharmacol. 2019 Aug 27;10:913. doi: 10.3389/fphar.2019.00913. eCollection 2019.
3
Linezolid as rescue therapy for pneumococcal meningitis.
Intensive Care Med. 2007 May;33(5):924-925. doi: 10.1007/s00134-007-0557-7. Epub 2007 Mar 13.
4
Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections.
Drugs. 2004;64(13):1433-64. doi: 10.2165/00003495-200464130-00004.
5
Activities of a new oral streptogramin, XRP 2868, compared to those of other agents against Streptococcus pneumoniae and haemophilus species.
Antimicrob Agents Chemother. 2003 Oct;47(10):3270-4. doi: 10.1128/AAC.47.10.3270-3274.2003.
6
Pharmacokinetics and efficacy of linezolid in a gerbil model of Streptococcus pneumoniae-induced acute otitis media.
Antimicrob Agents Chemother. 2003 Apr;47(4):1355-63. doi: 10.1128/AAC.47.4.1355-1363.2003.
7
Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci.
Antimicrob Agents Chemother. 2002 May;46(5):1273-80. doi: 10.1128/AAC.46.5.1273-1280.2002.
8
Linezolid: a review of its use in the management of serious gram-positive infections.
Drugs. 2001;61(4):525-51. doi: 10.2165/00003495-200161040-00008.
9
Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.
Clin Infect Dis. 2000 Aug;31(2):347-82. doi: 10.1086/313954. Epub 2000 Sep 7.
10
Linezolid.
Drugs. 2000 Apr;59(4):815-27; discussion 828. doi: 10.2165/00003495-200059040-00007.
本文引用的文献
1
Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829.
J Antimicrob Chemother. 1993 Feb;31(2):273-80. doi: 10.1093/jac/31.2.273.
2
Emergence of drug-resistant pneumococcal infections in the United States.
JAMA. 1994 Jun 15;271(23):1831-5.
3
Comparative activity of teicoplanin and vancomycin against 400 penicillin susceptible and resistant Streptococcus pneumoniae. The French Study Group.
Eur J Clin Microbiol Infect Dis. 1994 Jan;13(1):33-4. doi: 10.1007/BF02026121.
4
Management of infections caused by antibiotic-resistant Streptococcus pneumoniae.
N Engl J Med. 1994 Aug 11;331(6):377-82. doi: 10.1056/NEJM199408113310607.
5
Activity of oral antibiotics in middle ear and sinus infections caused by penicillin-resistant Streptococcus pneumoniae: implications for treatment.
Pediatr Infect Dis J. 1994 Jul;13(7):585-9. doi: 10.1097/00006454-199407000-00001.
6
In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993.
Antimicrob Agents Chemother. 1994 Oct;38(10):2419-25. doi: 10.1128/AAC.38.10.2419.
7
Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology.
Antimicrob Agents Chemother. 1994 Sep;38(9):2065-72. doi: 10.1128/AAC.38.9.2065.
8
In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir.
Antimicrob Agents Chemother. 1994 Dec;38(12):2902-4. doi: 10.1128/AAC.38.12.2902.
9
Comparative activity of ampicillin, amoxycillin, amoxycillin/clavulanate and cefotaxime against 189 penicillin-susceptible and -resistant pneumococci.
J Antimicrob Chemother. 1995 Jun;35(6):883-8. doi: 10.1093/jac/35.6.883.
10
Susceptibility of penicillin-resistant pneumococci to eighteen antimicrobials: implications for treatment of meningitis.
J Antimicrob Chemother. 1983 Aug;12(2):133-9. doi: 10.1093/jac/12.2.133.
Zotero 插件